Show simple item record

dc.contributor.authorNatuk, Robert J.
dc.contributor.authorBukowski, Jack F.
dc.contributor.authorBrubaker, Jeffery O.
dc.contributor.authorWelsh, Raymond M.
dc.date2022-08-11T08:09:02.000
dc.date.accessioned2022-08-23T16:16:04Z
dc.date.available2022-08-23T16:16:04Z
dc.date.issued1989-11-01
dc.date.submitted2008-11-24
dc.identifier.citation<p>J Virol. 1989 Nov;63(11):4969-71.</p>
dc.identifier.issn0022-538X (Print)
dc.identifier.pmid2795722
dc.identifier.urihttp://hdl.handle.net/20.500.14038/34243
dc.description.abstractLymphokine-activated killer (LAK) cells generated from C57BL/6 mouse spleen cells cultured with interleukin-2 are effective prophylactically against virus infection when inoculated at the site of virus injection. To predict the therapeutic efficacy of LAK cells, we determined whether LAK cells would home to sites of virus infection. In vitro, LAK cells responded chemotactically to cell-free peritoneal exudate fluids collected from virus-infected mice and to preparations of purified beta interferon. In vivo, radiolabeled LAK cells injected intravenously accumulated in the peritoneal cavities of intraperitoneally infected mice in amounts three to eight times greater than in uninfected mice. This ability to respond to chemotactic agents and migrate into sites of virus infection may make LAK cells useful as antiviral therapeutic agents.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2795722&dopt=Abstract">Link to article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC251148/
dc.subjectAnimals; Cells, Cultured; *Chemotaxis, Leukocyte; Interferon Type I; Interleukin-2; Killer Cells, Lymphokine-Activated; Mice; Mice, Inbred C57BL; Recombinant Proteins; Spleen; Vaccinia virus
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleAntiviral effect of lymphokine-activated killer cells: chemotaxis and homing to sites of virus infection
dc.typeJournal Article
dc.source.journaltitleJournal of virology
dc.source.volume63
dc.source.issue11
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/gsbs_sp/899
dc.identifier.contextkey671825
html.description.abstract<p>Lymphokine-activated killer (LAK) cells generated from C57BL/6 mouse spleen cells cultured with interleukin-2 are effective prophylactically against virus infection when inoculated at the site of virus injection. To predict the therapeutic efficacy of LAK cells, we determined whether LAK cells would home to sites of virus infection. In vitro, LAK cells responded chemotactically to cell-free peritoneal exudate fluids collected from virus-infected mice and to preparations of purified beta interferon. In vivo, radiolabeled LAK cells injected intravenously accumulated in the peritoneal cavities of intraperitoneally infected mice in amounts three to eight times greater than in uninfected mice. This ability to respond to chemotactic agents and migrate into sites of virus infection may make LAK cells useful as antiviral therapeutic agents.</p>
dc.identifier.submissionpathgsbs_sp/899
dc.contributor.departmentDepartment of Pathology
dc.contributor.departmentGraduate School of Biomedical Sciences
dc.source.pages4969-71


This item appears in the following Collection(s)

Show simple item record